FINWIRES · TerminalLIVE
FINWIRES

Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says

By

-- Bausch Health's (BHC) total prescriptions in Q1 were likely to be negatively impacted by the company's exit from the US federal drug pricing programs in October 2025, RBC Capital Markets said in a Monday note.

Prescriptions of the 550-miiligram formulation of the company's top-selling Xifaxan, used to treat gastrointestinal conditions, dropped 6.2% in Q1 year over year after a 1.1% decline in Q4, RBC analysts said. They expect volume losses to be partially offset by improved net pricing and revised their Xifaxan revenue forecast to $480 million from $487 million.

The company's Q1 revenue is projected at $2.43 billion, compared with the consensus of $2.41 billion, according to the note.

Investors are likely to focus on the ongoing litigation involving Xifaxan's patent; Bausch Health's plan to monetize the Bausch + Lomb (BLCO) asset after the genericization of Xifaxan, expected in January 2028; and a growth rebound for its Solta Medical aesthetics business, the analysts said.

Bausch Health is expected to report Q1 financial results after market-close on Wednesday.

RBC maintained the company's stock rating at sector-perform and lowered the price target to $9 from $10.

Price: $5.70, Change: $+0.07, Percent Change: +1.15%

Related Articles

Research

Research Alert: Oled Delivers Disappointing Results, Stable Guidance As Demand Remains Weak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OLED reported challenging Q1 results with revenue declining 14.5% Y/Y to $142M, well short of consensus expectations ($161M), while EPS of $0.76 fell 44% Y/Y and missed Street estimates ($1.20). The weakness was broad-based, with material sales down 2.9% to $84M and royalty/license fees declining 26.4% to $54M, representing the largest drag on quarterly performance. Management lowered 2026 revenue guidance to $650M from a prior $675M view, citing weak demand conditions. CFO noted near-term market conditions have become more measured while maintaining confidence in longer-term growth prospects, including Gen 8.6 capacity additions in Korea and China expected online this year. We agree with management's longer-term optimism but note weak current conditions may slow new OLED fab ramp timelines. We think the revised Q2-Q4 implied performance ($508M) creates room for downside risk below company projections, as the environment remains volatile.

$OLED
Asia

China Shipbuilding Industry's 2025 Profit Slips 7%, Revenue Rises 12%

China Shipbuilding Industry Group Power's (SHA:600482) net profit attributable to shareholders in 2025 slipped 6.5% to 1.30 billion yuan from 1.39 billion yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share declined 4.9% year on year to 0.58 yuan from 0.61 yuan.The Chinese shipbuilding conglomerate's operating revenue rose 12% to 57.80 billion yuan from 51.70 billion yuan in the prior year.

$SHA:600482
Equities

Mercuria Files Lawsuit Against Baltic Exchange Over TD3C Shipping Benchmark

Mercuria Energy Group said it has filed a lawsuit in London's High Court against Baltic Exchange Information Services, alleging distortion of a key oil shipping benchmark, Bloomberg reported on Thursday.The dispute centers on the TD3C route, which tracks the cost of shipping crude from the Middle East to China.Mercuria said the rate "no longer accurately or reliably represents the underlying market it is intended to measure," according to the claim form seen by Bloomberg, adding that the impact has led to losses estimated in the "hundreds of millions of US dollars."The Baltic Exchange, owned by Singapore Exchange, publishes freight rates widely used in global oil markets and derivatives trading.